GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 50 to 59 ...

It involves around seven hours of travel, including a two-hour ferry, if you’re coming from Canada’s largest city, Toronto. Priya and Yashan are on a road trip of Eastern Canada from India.

India and Canada have been dealing with an unprecedented diplomatic crisis after Canadian Prime Minister Justin Trudeau alleged that Indian government agents were involved in the killing of ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

India-Canada diplomatic ties soured further this week after allegations by Canadian federal police that "agents" of Delhi are working with organised criminals - including the Bishnoi gang linked ...

GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...

For the company’s closely watched respiratory syncytial virus (RSV) vaccine Arexvy, those challenges led to drastically reduced sales. After a stunning ascension to blockbuster status in its RSV ...

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...

His assignment was to help determine the boundary between Canada and the United States in order to clarify a treaty signed by Russia and Great Britain in 1825. While atop the mountain, he turned ...

Moderna says Health Canada has approved its mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and ...